✦ LIBER ✦

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions

✍ Scribed by Peter Valent; Günther Gastl; Klaus Geissler; Richard Greil; Oliver Hantschel; Alois Lang; Werner Linkesch; Thomas Lion; Andreas L. Petzer; Elisabeth Pittermann; Lisa Pleyer; Josef Thaler; Dominik Wolf

Book ID: 113555791
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 138 KB
Volume: 82
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2011.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib and nilotinib in first-line tr

Dasatinib and nilotinib in first-line treatment of chronic myeloid leukemia

✍ Jame Abraham 📂 Article 📅 2010 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 77 KB

Adherence to treatment with second-line

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

✍ Yood, Marianne Ulcickas; Oliveria, Susan A.; Cziraky, Mark; Hirji, Ishan; Hamdan 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 206 KB

First-line treatment of chronic myeloid

First-line treatment of chronic myeloid leukemia: imatinib versus nilotinib and dasatinib

✍ Nicholas J. DiBella 📂 Article 📅 2011 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 108 KB

Nilotinib as frontline therapy for patie

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

✍ Hirohisa Nakamae; Hirohiko Shibayama; Mineo Kurokawa; Tetsuya Fukuda; Chiaki Nak 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 289 KB

PCN47 COMPARISON OF HEALTH CARE RESOURCE

PCN47 COMPARISON OF HEALTH CARE RESOURCE UTILIZATION AND COSTS BETWEEN NILOTINIB AND DASATINIB AS SECOND LINE THERAPIES IN CHRONIC MYELOID LEUKEMIA (CML)

✍ EQ Wu; V Bollu; A Guo; A Guerin; M Tsaneva; D Williams; JD Griffin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Nilotinib is active in chronic and accel

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

✍ Giles, F J; Abruzzese, E; Rosti, G; Kim, D-W; Bhatia, R; Bosly, A; Goldberg, S; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB